VTRS · 8-K · 20261008PR039024

Acquisition / Partnership / Divestiture

Viatris Inc · 2026-10-08 · Importance 65 · Surprise 60 · In source text

On October 8, 2026, Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The acquisition adds Pacira’s U.S. products EXPAREL and ZILRETTA, and Viatris plans to expand their reach in selected international markets; Pacira reported approximately $746 million in revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026. Viatris expects the deal to be immediately accretive to its financial guidance metrics, funded primarily with excess cash and the remainder through short-term borrowings, with minimal impact on gross leverage; closing is expected by the end of 2026, subject to customary conditions including a regulatory waiting period.

Key facts

• Viatris agreed to acquire all outstanding Pacira common shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. source
• Viatris will commence a tender offer for all outstanding Pacira common shares at $36.50 per share in cash, followed by a second-step merger for the same consideration for shares not tendered. source
• The acquisition adds EXPAREL and ZILRETTA, two in-market U.S. products described as high-margin and patent-protected. source
• Viatris expects the transaction to be immediately accretive to its financial guidance metrics. source
• The transaction was unanimously approved by the boards of directors of Viatris and Pacira. source
• The acquisition is subject to customary closing conditions, including tender of a majority of Pacira’s outstanding shares and expiration of the applicable regulatory waiting period. source
• The transaction is expected to close by the end of 2026. source
• Upon completion of the transaction, Pacira will become a wholly owned subsidiary of Viatris. source

Impact estimates